Stockscreener 앱 받기
1.6389
1.50%
-0.0311
전일 마감가:
$1.67
열려 있는:
$1.68
하루 거래량:
555.37K
Relative Volume:
0.10
시가총액:
$260.49M
수익:
-
순이익/손실:
$-110.78M
주가수익비율:
-1.5317
EPS:
-1.07
순현금흐름:
$-75.59M
1주 성능:
-2.08%
1개월 성능:
-21.67%
6개월 성능:
+25.57%
1년 성능:
-69.48%
1일 변동 폭
$1.63
$1.68
1주일 범위
$1.60
$1.78
52주 변동 폭
$1.15
$6.77
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
HUMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.64 | 312.74M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.65 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
638.50 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.80 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.69 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.38 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-27 | 개시 | Barclays | Overweight |
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-11 | 개시 | H.C. Wainwright | Buy |
| 2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 개시 | Cowen | Outperform |
| 2021-09-24 | 개시 | Oppenheimer | Outperform |
| 2021-09-22 | 개시 | BTIG Research | Buy |
| 2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
Is Humacyte Inc. stock supported by strong cash flowsPortfolio Value Summary & Short-Term Swing Trade Alerts - newser.com
Can Humacyte Inc. stock reach $100 price targetWeekly Profit Analysis & Free High Accuracy Swing Entry Alerts - newser.com
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday? - AOL.com
Is Humacyte Inc. stock trading near support levels2025 Market Outlook & Low Risk Profit Maximizing Plans - newser.com
Technical analysis overview for Humacyte Inc. Equity Warrant stockCPI Data & Advanced Technical Analysis Signals - newser.com
Using data models to predict Humacyte Inc. Equity Warrant stock movementEntry Point & Free Verified High Yield Trade Plans - newser.com
Predicting Humacyte Inc. trend using moving averages2025 Investor Takeaways & Daily Technical Stock Forecast Reports - newser.com
Multi asset correlation models including Humacyte Inc. Equity Warrant2025 Fundamental Recap & Community Driven Trade Alerts - newser.com
Is Humacyte Inc. Equity Warrant stock vulnerable to regulatory risksWeekly Market Report & Long Hold Capital Preservation Tips - newser.com
Should I hold or sell Humacyte Inc. Equity Warrant stock in 2025Earnings Summary Report & Free AI Powered Buy and Sell Recommendations - newser.com
Is Humacyte Inc. Equity Warrant stock ready for a breakoutQuarterly Profit Summary & High Accuracy Investment Entry Signals - newser.com
Key metrics from Humacyte Inc.’s quarterly dataShare Buyback & Daily Volume Surge Trade Alerts - newser.com
Chart overlay techniques for tracking Humacyte Inc.July 2025 Snapshot & Community Verified Trade Alerts - newser.com
What recovery options are there for Humacyte Inc. Equity Warrant2025 Price Momentum & Low Drawdown Momentum Trade Ideas - newser.com
Will Humacyte Inc. stock benefit from infrastructure spendingWeekly Trading Summary & Risk Managed Investment Strategies - newser.com
Tick level data insight on Humacyte Inc. volatilityPortfolio Return Report & AI Enhanced Execution Alerts - newser.com
Is Humacyte Inc. Equity Warrant stock a dividend growth opportunityJuly 2025 Levels & Reliable Entry Point Alerts - newser.com
Earnings visualization tools for Humacyte Inc.July 2025 PreEarnings & Long-Term Capital Growth Strategies - newser.com
Will Humacyte Inc. stock deliver shareholder valueJuly 2025 Weekly Recap & Safe Swing Trade Setups - newser.com
Humacyte rises on Symvess sale to military treatment facility - MSN
Why Humacyte Inc. stock remains on buy listsMarket Trend Summary & High Accuracy Swing Trade Signals - newser.com
Why Humacyte Inc. Equity Warrant stock could outperform in 2025July 2025 Macro Moves & Community Verified Swing Trade Signals - newser.com
Will Humacyte Inc. Equity Warrant stock see insider buying2025 Earnings Impact & Fast Moving Trade Plans - newser.com
Historical volatility pattern of Humacyte Inc. Equity Warrant visualized2025 Buyback Activity & Target Return Focused Picks - newser.com
Tick level data insight on Humacyte Inc. Equity Warrant volatilityWatch List & Momentum Based Trading Ideas - newser.com
Using RSI to spot recovery in Humacyte Inc. Equity WarrantWeekly Investment Recap & Entry Point Confirmation Signals - newser.com
How Humacyte Inc. Equity Warrant stock performs in high volatility marketsPortfolio Return Summary & Precise Entry and Exit Recommendations - newser.com
Humacyte, Inc. (HUMA) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma - The Manila Times
Humacyte (NASDAQ: HUMA) says Symvess matches vein in limb trauma; 86.6% patency - Stock Titan
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.03%
0.32%
자본화:
|
볼륨(24시간):